美国CytoGenix
CytoGenix和Omnimmune签定了一项研发合作协议，它们将把CytoGenix的细胞内表达技术和Omnimmune的单克隆抗体结合起来，以促进用于诊断、预后、控制和防治癌症的基因制品的输送和靶向性。

CytoGenix的技术可生产未修饰的单链DNA(ssDNA)，这些ssDNA用于与反义技术、三联技术、DNA疫苗和aptamer相关的催化和治疗应用。而Omnimmune的技术将提高CytoGenix的载体对特定细胞系的靶向性，促进细胞对载体的摄取，并在细胞内复制多个特定ssDNA序列。
CytoGenix, Inc. is a biopharmaceutical company that develops and markets innovative compounds and services based on its proprietary gene regulating and DNA production technologies. CytoGenix has products in pre-clinical development including an antimicrobial compound, DNA vaccines and anti-herpes and anti-inflammatory topical creams. The Company has developed a cell free process for synthesizing DNA which it uses for its own products as well as marketing specific compounds to other companies. CytoGenix, Inc. currently has 11 granted patents (1 US, 1 China, 9 Europe) covering our basic ssDNA expression technology, with one additional allowance (India) pending. We have an additional 11 applications pending in various countries which are currently progressing through the normal prosecution process. The Company actively collaborates with numerous academic centers of excellence, government agencies and biotechnology industry partners. Cytogenix, Inc. is publicly traded under the symbol CYGX on the NASDAQ Over the Counter Bulletin Board.